GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (FRA:GOV) » Definitions » Cyclically Adjusted Revenue per Share

Insulet (FRA:GOV) Cyclically Adjusted Revenue per Share : €12.45 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Insulet Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Insulet's adjusted revenue per share for the three months ended in Mar. 2024 was €5.511. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €12.45 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Insulet's average Cyclically Adjusted Revenue Growth Rate was 16.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 20.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 20.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Insulet was 21.00% per year. The lowest was 3.70% per year. And the median was 19.40% per year.

As of today (2024-05-16), Insulet's current stock price is €165.50. Insulet's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €12.45. Insulet's Cyclically Adjusted PS Ratio of today is 13.29.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Insulet was 39.07. The lowest was 6.23. And the median was 17.72.


Insulet Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Insulet's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Cyclically Adjusted Revenue per Share Chart

Insulet Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.62 6.06 8.21 10.38 11.85

Insulet Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.69 11.16 12.03 11.85 12.45

Competitive Comparison of Insulet's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, Insulet's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insulet's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Insulet's Cyclically Adjusted PS Ratio falls into.



Insulet Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Insulet's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.511/131.7762*131.7762
=5.511

Current CPI (Mar. 2024) = 131.7762.

Insulet Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.956 100.560 1.253
201409 1.042 100.428 1.367
201412 0.219 99.070 0.291
201503 0.787 99.621 1.041
201506 0.950 100.684 1.243
201509 1.118 100.392 1.468
201512 1.351 99.792 1.784
201603 1.279 100.470 1.678
201606 1.359 101.688 1.761
201609 1.474 101.861 1.907
201612 1.709 101.863 2.211
201703 1.648 102.862 2.111
201706 1.685 103.349 2.148
201709 1.759 104.136 2.226
201712 1.894 104.011 2.400
201803 1.714 105.290 2.145
201806 1.808 106.317 2.241
201809 2.117 106.507 2.619
201812 2.141 105.998 2.662
201903 2.310 107.251 2.838
201906 2.549 108.070 3.108
201909 2.798 108.329 3.404
201912 2.943 108.420 3.577
202003 2.850 108.902 3.449
202006 3.064 108.767 3.712
202009 2.973 109.815 3.568
202012 3.020 109.897 3.621
202103 3.206 111.754 3.780
202106 3.275 114.631 3.765
202109 3.365 115.734 3.831
202112 3.750 117.630 4.201
202203 3.840 121.301 4.172
202206 4.084 125.017 4.305
202209 4.958 125.227 5.217
202212 4.874 125.222 5.129
202303 4.772 127.348 4.938
202306 5.218 128.729 5.342
202309 5.507 129.860 5.588
202312 5.552 129.419 5.653
202403 5.511 131.776 5.511

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Insulet  (FRA:GOV) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Insulet's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=165.50/12.45
=13.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Insulet was 39.07. The lowest was 6.23. And the median was 17.72.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Insulet Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Insulet's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Insulet (FRA:GOV) Business Description

Industry
Traded in Other Exchanges
Address
100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.

Insulet (FRA:GOV) Headlines

No Headlines